Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7384022 | 0.87 | NR1H2 (0.46) | NR1H2KDM4EPKMHPGDGPR119 | |
| SCHEMBL6749438 | 0.86 | NR1H2 (0.45) | NR1H2KDM4EPKMHPGDGPR119 | |
| SCHEMBL28646412 | 0.85 | DPP4 (0.46) | NR1H2KDM4EPKMHPGDGPR119 | |
| SCHEMBL7385084 | 0.85 | KDM4E (0.46) | NR1H2KDM4EPKMHPGDGPR119 | |
| SCHEMBL8634128 | 0.85 | KDM4E (0.46) | NR1H2KDM4EPKMHPGDGPR119 | |
| SCHEMBL23849943 | 0.85 | DPP4 (0.46) | NR1H2KDM4EPKMHPGDGPR119 | |
| SCHEMBL7943442 | 0.82 | KDM4E (0.50) | NR1H2KDM4EPKMHPGDGPR119 | |
| SCHEMBL18590725 | 0.82 | HPGD (0.48) | NR1H2KDM4EPKMHPGDGPR119 | |
| SCHEMBL16698964 | 0.81 | MEN1 (0.46) | NR1H2KDM4EPKMHPGDGPR119 | |
| SCHEMBL25547496 | 0.81 | KDM4E (0.49) | NR1H2KDM4EPKMHPGDGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | APOSENSE LTD. (IL) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | CD47, MCL1, BAD | NR1H2 1457/4885KDM4E 1405/4885PKM 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.